0001209191-19-008750.txt : 20190208
0001209191-19-008750.hdr.sgml : 20190208
20190208190949
ACCESSION NUMBER: 0001209191-19-008750
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190206
FILED AS OF DATE: 20190208
DATE AS OF CHANGE: 20190208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shukla Sanjay
CENTRAL INDEX KEY: 0001671026
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37378
FILM NUMBER: 19581463
MAIL ADDRESS:
STREET 1: C/O ATYR PHARMA, INC.
STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: aTYR PHARMA INC
CENTRAL INDEX KEY: 0001339970
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203435077
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-731-8389
MAIL ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-06
0
0001339970
aTYR PHARMA INC
LIFE
0001671026
Shukla Sanjay
3545 JOHN HOPKINS COURT, SUITE #250
SAN DIEGO
CA
92121
0
1
0
0
President and CEO
Employee Stock Option (right to buy)
0.5172
2019-02-06
4
A
0
200000
0.00
A
2029-02-06
Common Stock
200000
200000
D
Restricted Stock Unit
2019-02-06
4
A
0
50000
0.00
A
Common Stock
50000
50000
D
The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2019, such that this option will be fully exercisable on February 6, 2023. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
The RSUs are scheduled to vest in two equal annual installments beginning on February 6, 2020, such that the RSUs will fully vest on February 6, 2021. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Nancy D. Krueger, attorney-in-fact
2019-02-08